AstraZeneca has entered into a licensing agreement with CSPC Pharmaceuticals to acquire rights to eight early-stage weight management and type 2 diabetes programmes. The deal grants AstraZeneca access to CSPC’s AI-driven peptide discovery platform and its proprietary LiquidGel once-monthly injectable technology. Among the assets is SYH2082, a long-acting GLP-1/GIP dual agonist slated to begin Phase 1 trials imminently, alongside three additional preclinical injectable candidates and four discovery-stage projects. This collaboration complements AstraZeneca’s existing pipeline, which includes a small-molecule oral GLP-1 receptor agonist and two weekly injectable peptide agonists targeting GLP-1, glucagon and amylin receptors.

Under the terms of the agreement, AstraZeneca will pay CSPC $1.2 billion upon signing, with potential development and regulatory milestones of up to $3.5 billion payable over the life of the programmes. CSPC retains entitlement to commercial milestones—tiered royalties on global sales outside China—and will progress the first four programmes through Phase 1. Upon completion of those studies, AstraZeneca assumes responsibility for late-stage development and commercialization in all markets outside China, Taiwan, Hong Kong and Macau.

CSPC will retain exclusive rights to all eight assets within Greater China (China, Taiwan, Hong Kong and Macau), while AstraZeneca holds exclusive rights elsewhere. Following regulatory approvals in China, AstraZeneca has the option to co-commercialize select products alongside CSPC. The transaction is expected to close in the second quarter of 2026 and leverages AstraZeneca’s existing manufacturing footprint in Wuxi, Taizhou, Qingdao and Beijing, where the company already supplies medicines to over 70 markets worldwide.